Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for REPL

Stock Name	Replimune Group Inc
Ticker	REPL(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US76029N1063
LEI	549300AY704NEIRC4K64

Show aggregate REPL holdings

News associated with REPL

HC Wainwright Reaffirms “Neutral” Rating for Replimune Group (NASDAQ:REPL): Replimune Group (NASDAQ:REPL – Get Free Report)‘s stock had its “neutral” rating restated by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. Several other equities analysts have also recently commented on REPL. Barclays cut shares of Replimune Group from an “overweight” rating to an “equal weight” rating and dropped their target […] - 2025-09-10 03:00:56
Stocks Moving Premarket: PMNT, KULR, ENLV, ORGN, And Other Gainers & Losers: (RTTNews) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell. - 2025-08-15 08:58:21
Zurcher Kantonalbank Zurich Cantonalbank Purchases 5,876 Shares of Replimune Group, Inc. (NASDAQ:REPL): Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 106.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,410 shares of the company’s stock after purchasing an additional 5,876 shares during the period. […] - 2025-08-11 05:32:47
Wednesday's ETF Movers: XBI, OIH: In trading on Wednesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 1.8% on the day. Components of that ETF showing particular strength include shares of Replimune Group, up about 104.8% and shares of Biohaven, up about 18.9% on the day. And underperfor - 2025-07-30 14:51:58
Wednesday Sector Leaders: Music & Electronics Stores, Biotechnology Stocks: In trading on Wednesday, music & electronics stores shares were relative leaders, up on the day by about 5.7%. Leading the group were shares of Global Industrial, up about 21.2% and shares of Vertiv Holdings up about 2.3% on the day. Also showing relative strength are biot - 2025-07-30 14:51:45
Replimune Group, Inc. (NASDAQ:REPL) Receives $21.00 Average PT from Analysts: Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) has been assigned a consensus recommendation of “Hold” from the twelve brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have issued a buy rating and one has given […] - 2025-07-25 05:48:57
Replimune Group (NASDAQ:REPL) Hits New 52-Week Low After Analyst Downgrade: Replimune Group, Inc. (NASDAQ:REPL – Get Free Report)’s stock price hit a new 52-week low on Tuesday after Barclays downgraded the stock from an overweight rating to an equal weight rating. Barclays now has a $3.00 price target on the stock, down from their previous price target of $17.00. Replimune Group traded as low as […] - 2025-07-24 04:24:56
Pre-Market Most Active for Jul 22, 2025 : OPEN, TSLL, REPL, SQQQ, OSCR, NVDA, QS, RXRX, BBAI, JOBY, NIO, CVX: The NASDAQ 100 Pre-Market Indicator is down -5.34 to 23,174.72. The total Pre-Market volume is currently 168,215,532 shares traded.The following are the most active stocks for the pre-market session: Opendoor Technologies Inc (OPEN) is +0.62 at $3.83, with 67,855,698 shares trad - 2025-07-22 09:29:55
Replimune Group (NASDAQ:REPL) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says: Replimune Group (NASDAQ:REPL – Get Free Report) had its target price increased by research analysts at JPMorgan Chase & Co. from $16.00 to $19.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 52.00% […] - 2025-07-18 05:05:13
Replimune Group (NASDAQ:REPL) Shares Gap Up Following Analyst Upgrade: Replimune Group, Inc. (NASDAQ:REPL – Get Free Report)’s stock price gapped up before the market opened on Wednesday after JPMorgan Chase & Co. raised their price target on the stock from $16.00 to $19.00. The stock had previously closed at $12.40, but opened at $13.19. JPMorgan Chase & Co. currently has an overweight rating on […] - 2025-07-18 02:20:52
LABU's Holdings Imply 58% Gain Potential: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-10 07:59:01
Exchange Traded Concepts LLC Sells 5,196 Shares of Replimune Group, Inc. (NASDAQ:REPL): Exchange Traded Concepts LLC trimmed its stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 32.5% in the first quarter, HoldingsChannel.com reports. The firm owned 10,814 shares of the company’s stock after selling 5,196 shares during the period. Exchange Traded Concepts LLC’s holdings in Replimune Group were worth $105,000 at the end of the […] - 2025-06-25 04:57:01
California State Teachers Retirement System Raises Stake in Replimune Group, Inc. (NASDAQ:REPL): California State Teachers Retirement System boosted its position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 25.9% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 42,725 shares of the company’s stock after purchasing an additional 8,793 shares during the period. California State Teachers Retirement System’s holdings in Replimune Group were worth […] - 2025-06-12 04:52:49
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $796,000 Stake in Replimune Group, Inc. (NASDAQ:REPL): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 19.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 65,762 shares of the company’s stock after selling 15,402 […] - 2025-06-11 04:38:55
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.43 Consensus PT from Analysts: Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) has earned an average rating of “Buy” from the nine analysts that are presently covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price […] - 2025-06-03 03:07:12
Two Sigma Investments LP Buys 33,346 Shares of Replimune Group, Inc. (NASDAQ:REPL): Two Sigma Investments LP boosted its stake in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 18.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 212,586 shares of the company’s stock after acquiring an additional 33,346 shares during […] - 2025-06-01 06:37:00
Replimune Group, Inc. (NASDAQ:REPL) Stock Position Lifted by ProShare Advisors LLC: ProShare Advisors LLC grew its position in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 33.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,788 shares of the company’s stock after buying an additional 5,247 shares during the […] - 2025-06-01 05:46:47
Thursday's ETF Movers: XBI, URA: In trading on Thursday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 1.9% on the day. Components of that ETF showing particular strength include shares of Oric Pharmaceuticals, up about 33.8% and shares of Replimune Group, up about 9.6% on the day. And un - 2025-05-29 12:59:01
Two Sigma Advisers LP Lowers Position in Replimune Group, Inc. (NASDAQ:REPL): Two Sigma Advisers LP decreased its position in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 9.6% during the fourth quarter, Holdings Channel reports. The fund owned 170,400 shares of the company’s stock after selling 18,000 shares during the period. Two Sigma Advisers LP’s holdings in Replimune Group were worth $2,064,000 as of […] - 2025-05-29 05:52:49
Nuveen Asset Management LLC Boosts Stake in Replimune Group, Inc. (NASDAQ:REPL): Nuveen Asset Management LLC lifted its stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 108.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 667,634 shares of the company’s stock after purchasing an additional 347,993 shares during the period. Nuveen Asset […] - 2025-05-29 04:56:55
Quantinno Capital Management LP Invests $127,000 in Replimune Group, Inc. (NASDAQ:REPL): Quantinno Capital Management LP acquired a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,455 shares of the company’s stock, valued at approximately $127,000. Other institutional investors and […] - 2025-05-28 05:08:55
Investors Buy High Volume of Replimune Group Call Options (NASDAQ:REPL): Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) saw some unusual options trading on Thursday. Traders acquired 5,508 call options on the stock. This is an increase of approximately 652% compared to the average volume of 732 call options. Insider Buying and Selling at Replimune Group In other Replimune Group news, CAO Andrew Schwendenman sold […] - 2025-05-23 02:01:01
Hsbc Holdings PLC Buys Shares of 14,008 Replimune Group, Inc. (NASDAQ:REPL): Hsbc Holdings PLC purchased a new position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) during the 4th quarter, HoldingsChannel reports. The firm purchased 14,008 shares of the company’s stock, valued at approximately $175,000. Several other hedge funds also recently modified their holdings of the business. Sterling Capital Management LLC increased its position in Replimune […] - 2025-05-12 04:56:47
Barclays PLC Raises Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL): Barclays PLC boosted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 5.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 167,329 shares of the company’s stock after acquiring an additional 8,838 shares during the quarter. […] - 2025-05-02 06:03:01
Invesco Ltd. Trims Stock Position in Replimune Group, Inc. (NASDAQ:REPL): Invesco Ltd. cut its holdings in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 51.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 88,006 shares of the company’s stock after selling 92,952 shares during the period. Invesco Ltd.’s holdings in Replimune Group were worth $1,066,000 […] - 2025-05-02 04:30:49
Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Wells Fargo & Company MN: Wells Fargo & Company MN boosted its holdings in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 102.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 77,371 shares of the company’s stock after acquiring an additional 39,121 shares during the period. Wells Fargo & Company MN’s holdings in Replimune Group were worth $937,000 as […] - 2025-04-30 05:14:51
Legal & General Group Plc Acquires 17,597 Shares of Replimune Group, Inc. (NASDAQ:REPL): Legal & General Group Plc lifted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 42.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,366 shares of the company’s stock after purchasing an additional 17,597 shares during the […] - 2025-04-29 04:50:50
Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $19.43: Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) has been given an average rating of “Buy” by the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target […] - 2025-04-14 02:59:04
Corebridge Financial Inc. Sells 2,284 Shares of Replimune Group, Inc. (NASDAQ:REPL): Corebridge Financial Inc. trimmed its holdings in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 7.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 30,267 shares of the company’s stock after selling 2,284 shares during the period. Corebridge Financial Inc.’s holdings in Replimune Group were worth $367,000 at the end of the most […] - 2025-04-10 05:33:06

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) REPL holdings

Date	Number of REPL Shares Held	Base Market Value of REPL Shares	Local Market Value of REPL Shares	Change in REPL Shares Held	Change in REPL Base Value	Current Price per REPL Share Held	Previous Price per REPL Share Held
2025-11-11 (Tuesday)	51,368	USD 468,990	USD 468,990	0	USD 21,575	USD 9.13	USD 8.70999
2025-11-10 (Monday)	51,368	USD 447,415	USD 447,415	133	USD 21,652	USD 8.70999	USD 8.31
2025-11-07 (Friday)	51,235	USD 425,763	USD 425,763	0	USD -9,735	USD 8.31	USD 8.50001
2025-11-06 (Thursday)	51,235	USD 435,498	USD 435,498	133	USD -2,957	USD 8.50001	USD 8.58
2025-11-05 (Wednesday)	51,102	USD 438,455	USD 438,455	0	USD -19,930	USD 8.58	USD 8.97
2025-11-04 (Tuesday)	51,102	USD 458,385	USD 458,385	133	USD -15,882	USD 8.97	USD 9.30501
2025-11-03 (Monday)	50,969	USD 474,267	USD 474,267	0	USD -21,661	USD 9.30501	USD 9.72999
2025-10-31 (Friday)	50,969	USD 495,928	USD 495,928	0	USD -26,504	USD 9.72999	USD 10.25
2025-10-30 (Thursday)	50,969	USD 522,432	USD 522,432	665	USD 8,828	USD 10.25	USD 10.21
2025-10-29 (Wednesday)	50,304	USD 513,604	USD 513,604	266	USD -9,293	USD 10.21	USD 10.45
2025-10-28 (Tuesday)	50,038	USD 522,897	USD 522,897	0	USD 56,042	USD 10.45	USD 9.33001
2025-10-27 (Monday)	50,038	USD 466,855	USD 466,855	0	USD 26,521	USD 9.33001	USD 8.79999

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REPL by Blackrock for IE00BDZVHG35

Show aggregate share trades of REPL

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 133 8.750 8.325 8.367 USD 1,113 10.35
2025-11-06 BUY 133 8.640 8.280 8.316 USD 1,106 10.37
2025-11-04 BUY 133 9.410 8.910 8.960 USD 1,192 10.39
2025-10-30 BUY 665 10.450 10.035 10.076 USD 6,701 10.40
2025-10-29 BUY 266 10.210 10.610 10.570 USD 2,812 10.40
2025-10-22 SELL -532 8.300 8.360 8.354 USD -4,444 10.44 Profit of 1,107 on sale
2025-10-21 BUY 268 8.100 9.450 9.315 USD 2,496 10.45
2025-10-17 BUY 668 4.500 4.750 4.725 USD 3,156 10.49
2025-10-15 BUY 1,064 4.740 4.750 4.749 USD 5,053 10.53
2025-10-03 BUY 952 4.730 4.770 4.766 USD 4,537 10.60
2025-10-02 BUY 137 4.650 4.690 4.686 USD 642 10.63
2025-09-30 BUY 272 4.190 4.360 4.343 USD 1,181 10.71
2025-09-26 BUY 274 4.130 4.200 4.193 USD 1,149 10.79
2025-09-25 BUY 274 4.050 4.110 4.104 USD 1,124 10.84
2025-09-17 BUY 411 5.710 5.930 5.908 USD 2,428 10.91
2025-07-17 SELL -264 12.500 12.850 12.815 USD -3,383 10.92 Loss of -500 on sale
2025-07-11 SELL -1,064 10.970 11.290 11.258 USD -11,979 10.90 Loss of -385 on sale
2025-07-02 BUY 7,315 9.550 9.700 9.685 USD 70,846 10.92
2025-06-25 BUY 266 9.450 9.930 9.882 USD 2,629 10.96
2025-06-11 BUY 268 9.780 10.235 10.189 USD 2,731 11.06
2025-06-10 BUY 268 10.130 10.495 10.458 USD 2,803 11.07
2025-06-04 SELL -134 9.690 10.380 10.311 USD -1,382 11.11 Profit of 106 on sale
2025-04-23 BUY 133 8.830 9.340 9.289 USD 1,235 11.87
2025-04-10 SELL -1,072 6.920 7.320 7.280 USD -7,804 12.28 Profit of 5,357 on sale
2025-04-08 SELL -133 7.140 7.970 7.887 USD -1,049 12.39 Profit of 599 on sale
2025-04-07 SELL -133 7.490 7.780 7.751 USD -1,031 12.45 Profit of 625 on sale
2025-04-04 SELL -670 7.460 7.799 7.765 USD -5,203 12.51 Profit of 3,178 on sale
2025-04-01 BUY 2,859 8.400 9.680 9.552 USD 27,309 12.61
2025-03-31 SELL -378 9.750 10.190 10.146 USD -3,835 12.64 Profit of 943 on sale
2025-03-14 SELL -2,032 11.655 12.120 12.073 USD -24,533 12.88 Profit of 1,646 on sale
2025-03-07 SELL -252 11.510 12.015 11.965 USD -3,015 12.98 Profit of 256 on sale
2025-03-04 SELL -126 12.020 12.410 12.371 USD -1,559 13.03 Profit of 83 on sale
2025-02-25 BUY 252 13.490 13.720 13.697 USD 3,452 13.04
2025-02-19 SELL -125 13.780 14.450 14.383 USD -1,798 12.98 Loss of -176 on sale
2025-02-13 BUY 375 14.290 14.480 14.461 USD 5,423 12.89
2025-02-12 BUY 125 13.790 13.850 13.844 USD 1,731 12.87
2025-02-11 BUY 500 12.850 13.030 13.012 USD 6,506 12.87
2025-01-02 BUY 1,940 12.560 13.560 13.460 USD 26,112 12.51
2024-12-30 SELL -609 12.330 12.525 12.505 USD -7,616 12.51 Profit of 4 on sale
2024-11-18 SELL -1,785 10.770 10.980 10.959 USD -19,562 12.04 Profit of 1,936 on sale
2024-11-08 SELL -119 12.440 12.780 12.746 USD -1,517 12.01 Loss of -88 on sale
2024-10-21 SELL -120 11.350 11.590 11.566 USD -1,388 0.00 Loss of -1,388 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	133	8.750	8.325	8.367	USD 1,113	10.35
2025-11-06	BUY	133	8.640	8.280	8.316	USD 1,106	10.37
2025-11-04	BUY	133	9.410	8.910	8.960	USD 1,192	10.39
2025-10-30	BUY	665	10.450	10.035	10.076	USD 6,701	10.40
2025-10-29	BUY	266	10.210	10.610	10.570	USD 2,812	10.40
2025-10-22	SELL	-532	8.300	8.360	8.354	USD -4,444	10.44 Profit of 1,107 on sale
2025-10-21	BUY	268	8.100	9.450	9.315	USD 2,496	10.45
2025-10-17	BUY	668	4.500	4.750	4.725	USD 3,156	10.49
2025-10-15	BUY	1,064	4.740	4.750	4.749	USD 5,053	10.53
2025-10-03	BUY	952	4.730	4.770	4.766	USD 4,537	10.60
2025-10-02	BUY	137	4.650	4.690	4.686	USD 642	10.63
2025-09-30	BUY	272	4.190	4.360	4.343	USD 1,181	10.71
2025-09-26	BUY	274	4.130	4.200	4.193	USD 1,149	10.79
2025-09-25	BUY	274	4.050	4.110	4.104	USD 1,124	10.84
2025-09-17	BUY	411	5.710	5.930	5.908	USD 2,428	10.91
2025-07-17	SELL	-264	12.500	12.850	12.815	USD -3,383	10.92 Loss of -500 on sale
2025-07-11	SELL	-1,064	10.970	11.290	11.258	USD -11,979	10.90 Loss of -385 on sale
2025-07-02	BUY	7,315	9.550	9.700	9.685	USD 70,846	10.92
2025-06-25	BUY	266	9.450	9.930	9.882	USD 2,629	10.96
2025-06-11	BUY	268	9.780	10.235	10.189	USD 2,731	11.06
2025-06-10	BUY	268	10.130	10.495	10.458	USD 2,803	11.07
2025-06-04	SELL	-134	9.690	10.380	10.311	USD -1,382	11.11 Profit of 106 on sale
2025-04-23	BUY	133	8.830	9.340	9.289	USD 1,235	11.87
2025-04-10	SELL	-1,072	6.920	7.320	7.280	USD -7,804	12.28 Profit of 5,357 on sale
2025-04-08	SELL	-133	7.140	7.970	7.887	USD -1,049	12.39 Profit of 599 on sale
2025-04-07	SELL	-133	7.490	7.780	7.751	USD -1,031	12.45 Profit of 625 on sale
2025-04-04	SELL	-670	7.460	7.799	7.765	USD -5,203	12.51 Profit of 3,178 on sale
2025-04-01	BUY	2,859	8.400	9.680	9.552	USD 27,309	12.61
2025-03-31	SELL	-378	9.750	10.190	10.146	USD -3,835	12.64 Profit of 943 on sale
2025-03-14	SELL	-2,032	11.655	12.120	12.073	USD -24,533	12.88 Profit of 1,646 on sale
2025-03-07	SELL	-252	11.510	12.015	11.965	USD -3,015	12.98 Profit of 256 on sale
2025-03-04	SELL	-126	12.020	12.410	12.371	USD -1,559	13.03 Profit of 83 on sale
2025-02-25	BUY	252	13.490	13.720	13.697	USD 3,452	13.04
2025-02-19	SELL	-125	13.780	14.450	14.383	USD -1,798	12.98 Loss of -176 on sale
2025-02-13	BUY	375	14.290	14.480	14.461	USD 5,423	12.89
2025-02-12	BUY	125	13.790	13.850	13.844	USD 1,731	12.87
2025-02-11	BUY	500	12.850	13.030	13.012	USD 6,506	12.87
2025-01-02	BUY	1,940	12.560	13.560	13.460	USD 26,112	12.51
2024-12-30	SELL	-609	12.330	12.525	12.505	USD -7,616	12.51 Profit of 4 on sale
2024-11-18	SELL	-1,785	10.770	10.980	10.959	USD -19,562	12.04 Profit of 1,936 on sale
2024-11-08	SELL	-119	12.440	12.780	12.746	USD -1,517	12.01 Loss of -88 on sale
2024-10-21	SELL	-120	11.350	11.590	11.566	USD -1,388	0.00 Loss of -1,388 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REPL

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	1,155,271	79,780	3,328,204	34.7%
2025-09-18	6,516,587	175,106	16,426,643	39.7%
2025-09-17	368,510	5,734	873,880	42.2%
2025-09-16	416,993	0	1,186,291	35.2%
2025-09-15	306,663	19,916	1,348,602	22.7%
2025-09-12	159,691	377	627,152	25.5%
2025-09-11	310,480	562	940,450	33.0%
2025-09-10	228,463	3,406	839,426	27.2%
2025-09-09	207,407	0	677,819	30.6%
2025-09-08	192,041	100	1,439,099	13.3%
2025-09-05	236,056	0	1,545,926	15.3%
2025-09-04	429,366	2,400	891,490	48.2%
2025-09-03	286,924	0	947,242	30.3%
2025-09-02	481,113	472	1,709,094	28.2%
2025-08-29	221,794	6	731,794	30.3%
2025-08-28	195,280	5,032	457,353	42.7%
2025-08-27	168,346	0	383,243	43.9%
2025-08-26	144,359	1,157	405,921	35.6%
2025-08-25	211,801	0	572,400	37.0%
2025-08-22	399,862	0	984,910	40.6%
2025-08-21	460,150	2,732	1,311,407	35.1%
2025-08-20	231,234	2,167	622,090	37.2%
2025-08-19	258,324	10,646	706,871	36.5%
2025-08-18	405,409	25,490	1,156,110	35.1%
2025-08-15	949,098	1	2,216,166	42.8%
2025-08-14	384,951	731	1,393,003	27.6%
2025-08-13	538,873	0	1,384,601	38.9%
2025-08-12	303,245	31,505	1,531,279	19.8%
2025-08-11	562,239	16,097	2,419,846	23.2%
2025-08-08	1,116,754	1	1,987,843	56.2%
2025-08-07	653,638	50,092	2,515,400	26.0%
2025-08-06	1,249,433	9,261	3,550,152	35.2%
2025-08-05	1,163,520	26,410	3,477,264	33.5%
2025-08-04	2,738,143	249,408	8,569,066	32.0%
2025-08-01	1,847,429	151,128	4,123,427	44.8%
2025-07-31	3,517,615	319,081	9,025,987	39.0%
2025-07-30	35,205,916	228,534	84,188,538	41.8%
2025-07-29	7,579,232	22,622	15,076,443	50.3%
2025-07-28	923,369	112	3,198,846	28.9%
2025-07-25	708,652	8,003	2,864,430	24.7%
2025-07-24	1,532,172	8,457	6,415,576	23.9%
2025-07-23	6,581,948	689,136	23,556,734	27.9%
2025-07-22	24,781,022	2,885,921	37,903,813	65.4%
2025-07-21	1,187,815	1,600	1,778,068	66.8%
2025-07-18	689,488	91	1,366,951	50.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE